TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of AZD0530 in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
Brief Summary: The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: CCI-779 (temsirolimus) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: CCI-779 (temsirolimus) | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: CCI-779 (temsirolimus); Assigned to Arm(s): A, B
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
D: Arm Label: Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD0530, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: AZD0530; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2, Active Comparator | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2, Active Comparator

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of AZD0530 in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
Brief Summary: The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer


Options:
A: Arm Label: Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD0530, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: AZD0530; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2, Active Comparator | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2, Active Comparator
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: CCI-779 (temsirolimus) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: CCI-779 (temsirolimus) | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: CCI-779 (temsirolimus); Assigned to Arm(s): A, B
C: Arm Label: Treatment (temsirolimus); Type: EXPERIMENTAL; Interventions: Drug: temsirolimus | Intervention Type: DRUG; Name: temsirolimus; Assigned to Arm(s): Treatment (temsirolimus)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Therapy in the Treatment of Adolescent Anorexia Nervosa
Brief Summary: This study will compare the effectiveness of two different family treatments for the treatment of adolescent anorexia nervosa.


Options:
A: Arm Label: Exposure and Response Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP) | Arm Label: Cognitive Behavior Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Intervention Type: BEHAVIORAL; Name: Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP); Assigned to Arm(s): Exposure and Response Prevention | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): Cognitive Behavior Therapy
B: Arm Label: Cognitive behavioral counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Identity Intervention Program | Arm Label: Supportive therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Psychotherapy for the Eating Disorders | Intervention Type: BEHAVIORAL; Name: Identity Intervention Program; Assigned to Arm(s): Cognitive behavioral counseling | Intervention Type: BEHAVIORAL; Name: Supportive Psychotherapy for the Eating Disorders; Assigned to Arm(s): Supportive therapy
C: Arm Label: Family Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Family Behavior Therapy | Arm Label: Systems Family Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Systems Family Therapy | Intervention Type: BEHAVIORAL; Name: Family Behavior Therapy; Assigned to Arm(s): Family Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Systems Family Therapy; Assigned to Arm(s): Systems Family Therapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Family Based Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ego-Oriented Individual Psychotherapy | Intervention Type: BEHAVIORAL; Name: Family Based Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Ego-Oriented Individual Psychotherapy; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT of Supplemented Docosahexaenoic Acid and Gross Motor Development Milestones in Healthy Infants.
Brief Summary: To examine whether daily supplement of docosahexaenoic acid throughout the first year of life may speed up the achievement of gross motor development milestones in healthy infants, a total of 1160 healthy infants randomly allocated to receive throughout the first year of life daily oral supplement of vitamin D3 (400 IU) plus docosahexaenoic acid (20 mg) or vitamin D3 (400 IU) alone. Primary outcome measure: time of achieving gross motor development milestones. Secondary outcome measure: time of achieving early fine motor development milestones and language.


Options:
A: Arm Label: low docosahexaenoic acid formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: low docosahexaenoic acid formula | Arm Label: medium docosahexaenoic acid formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: medium docosahexaenoic acid formula | Arm Label: high docosahexaenoic acid formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: high docosahexaenoic acid formula | Arm Label: human milk; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: low docosahexaenoic acid formula; Assigned to Arm(s): low docosahexaenoic acid formula | Intervention Type: DIETARY_SUPPLEMENT; Name: medium docosahexaenoic acid formula; Assigned to Arm(s): medium docosahexaenoic acid formula | Intervention Type: DIETARY_SUPPLEMENT; Name: high docosahexaenoic acid formula; Assigned to Arm(s): high docosahexaenoic acid formula | Intervention Type: DIETARY_SUPPLEMENT; Name: breast milk; Assigned to Arm(s): human milk
B: Arm Label: Fish Oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fish Oil | Arm Label: Sunflower oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Sunflower Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish Oil; Assigned to Arm(s): Fish Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Sunflower Oil; Assigned to Arm(s): Sunflower oil
C: Arm Label: standard infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: standard infant formula | Arm Label: modified infant formula; Type: EXPERIMENTAL; Interventions: Other: modified infant formula | Arm Label: breast milk; Type: OTHER; Interventions: Other: breast milk | Intervention Type: OTHER; Name: standard infant formula; Assigned to Arm(s): standard infant formula | Intervention Type: OTHER; Name: modified infant formula; Assigned to Arm(s): modified infant formula | Intervention Type: OTHER; Name: breast milk; Assigned to Arm(s): breast milk
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Docosahexaenoic acid (DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: Docosahexaenoic acid (DHA); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT of Supplemented Docosahexaenoic Acid and Gross Motor Development Milestones in Healthy Infants.
Brief Summary: To examine whether daily supplement of docosahexaenoic acid throughout the first year of life may speed up the achievement of gross motor development milestones in healthy infants, a total of 1160 healthy infants randomly allocated to receive throughout the first year of life daily oral supplement of vitamin D3 (400 IU) plus docosahexaenoic acid (20 mg) or vitamin D3 (400 IU) alone. Primary outcome measure: time of achieving gross motor development milestones. Secondary outcome measure: time of achieving early fine motor development milestones and language.


Options:
A: Arm Label: DHA capsules; Type: EXPERIMENTAL; Interventions: Drug: DHA | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo capsule | Intervention Type: DRUG; Name: DHA; Assigned to Arm(s): DHA capsules | Intervention Type: OTHER; Name: Placebo capsule; Assigned to Arm(s): Placebo capsules
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Docosahexaenoic acid (DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: Docosahexaenoic acid (DHA); Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 4; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: DHA and ARA; Assigned to Arm(s): 1, 2, 3 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): 4
D: Arm Label: standard infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: standard infant formula | Arm Label: modified infant formula; Type: EXPERIMENTAL; Interventions: Other: modified infant formula | Arm Label: breast milk; Type: OTHER; Interventions: Other: breast milk | Intervention Type: OTHER; Name: standard infant formula; Assigned to Arm(s): standard infant formula | Intervention Type: OTHER; Name: modified infant formula; Assigned to Arm(s): modified infant formula | Intervention Type: OTHER; Name: breast milk; Assigned to Arm(s): breast milk

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder.
Brief Summary: To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder


Options:
A: Intervention Type: DRUG; Name: SPM 907; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine ER | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): 3
C: Arm Label: Fesoterodine (Double-Blind); Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Arm Label: Placebo (Double-Blind); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): Fesoterodine (Double-Blind) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Double-Blind)
D: Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Brief Summary: The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.


Options:
A: Arm Label: Lithium plus Divalproex; Type: EXPERIMENTAL; Interventions: Drug: Lithium, Drug: Divalproex | Arm Label: Lithium plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lithium, Drug: Placebo | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): Lithium plus Divalproex, Lithium plus placebo | Intervention Type: DRUG; Name: Divalproex; Assigned to Arm(s): Lithium plus Divalproex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Lithium plus placebo
B: Arm Label: Topiramate; Type: EXPERIMENTAL; Interventions: Drug: Topiramate + Cognitive Behavioral Therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Cognitive Behavioral Therapy | Intervention Type: DRUG; Name: Topiramate + Cognitive Behavioral Therapy; Assigned to Arm(s): Topiramate | Intervention Type: DRUG; Name: Placebo + Cognitive Behavioral Therapy; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vigabatrin, Behavioral: Group therapy | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Group therapy | Intervention Type: DRUG; Name: Vigabatrin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B | Intervention Type: BEHAVIORAL; Name: Group therapy; Assigned to Arm(s): A, B
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: vigabatrin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vigabatrin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Atorvastatin on the Occurrence of Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Grafting Surgery
Brief Summary: The purpose of this study is to determine whether pretreatment with atorvastatin protects against atrial fibrillation following off-pump coronary artery bypass graft surgery.


Options:
A: Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
B: Arm Label: High dose Atorvastatin 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Control, High dose Atorvastatin 80 mg
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rosuvastatin | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: rosuvastatin | Intervention Type: DRUG; Name: rosuvastatin; Assigned to Arm(s): 1, control
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: atorvastatin | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY
Brief Summary: The duration of dual antiplatelet treatment (i.e. asprin and clopidogrel) after drug-eluting stent implantation is highly debated. This study will evaluate the value of extending such treatment up to 2 years after the procedure as compared to conventional treatment according to our national health institute guidelines (i.e. minimum 1 month after bare metal stent and 6 months after drug-eluting stent) on the composite endpoint of death, MI or stroke.


Options:
A: Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: standard medication; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): aspirin
B: Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: clopidogrel treatment after bare metal stent implantation, Drug: clopidogrel after zotarolimus-eluting stent implantation, Drug: clopidogrel after paclitaxel-eluting stent implantation, Drug: clopidogrel after everolimus-eluting stent implantation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: clopidogrel treatment after bare metal stent implantation, Drug: clopidogrel after zotarolimus-eluting stent implantation, Drug: clopidogrel after paclitaxel-eluting stent implantation, Drug: clopidogrel after everolimus-eluting stent implantation | Intervention Type: DRUG; Name: clopidogrel treatment after bare metal stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel treatment after bare metal stent implantation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: clopidogrel after zotarolimus-eluting stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel after paclitaxel-eluting stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel after everolimus-eluting stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel after zotarolimus-eluting stent implantation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: clopidogrel after paclitaxel-eluting stent implantation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: clopidogrel after everolimus-eluting stent implantation; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: clopidogrel (SR25990); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Study of Tai Chi Exercise in Relation to Balance in Persons With Parkinson's Disease
Brief Summary: Patients practicing Tai Chi will exhibit significant improvements in primary outcome measures of balance, and secondary outcomes of gait, physical performance, Unified Parkinson's Disease Rating Scale, Falls, muscle strength.


Options:
A: Arm Label: TT+VR; Type: EXPERIMENTAL; Interventions: Other: TT+VR | Arm Label: TT alone; Type: ACTIVE_COMPARATOR; Interventions: Other: TT alone | Intervention Type: OTHER; Name: TT+VR; Assigned to Arm(s): TT+VR | Intervention Type: OTHER; Name: TT alone; Assigned to Arm(s): TT alone
B: Arm Label: IPX066; Type: EXPERIMENTAL; Interventions: Drug: IPX066, Drug: IR CD-LD | Arm Label: IR CD-LD; Type: ACTIVE_COMPARATOR; Interventions: Drug: IPX066, Drug: IR CD-LD | Intervention Type: DRUG; Name: IPX066; Assigned to Arm(s): IPX066, IR CD-LD | Intervention Type: DRUG; Name: IR CD-LD; Assigned to Arm(s): IPX066, IR CD-LD
C: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi | Arm Label: B. Strength training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Strength training | Arm Label: C. Low-Impact; Type: OTHER; Interventions: Behavioral: Low-Impact Exercise Control | Intervention Type: BEHAVIORAL; Name: Tai Chi; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): B. Strength training | Intervention Type: BEHAVIORAL; Name: Low-Impact Exercise Control; Assigned to Arm(s): C. Low-Impact

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Study of Tai Chi Exercise in Relation to Balance in Persons With Parkinson's Disease
Brief Summary: Patients practicing Tai Chi will exhibit significant improvements in primary outcome measures of balance, and secondary outcomes of gait, physical performance, Unified Parkinson's Disease Rating Scale, Falls, muscle strength.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Physical Therapy aimed to improve Physical Activity | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical therapy aimed to move safely | Intervention Type: OTHER; Name: Physical therapy aimed to move safely; Assigned to Arm(s): B | Intervention Type: OTHER; Name: Physical Therapy aimed to improve Physical Activity; Assigned to Arm(s): A
B: Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi | Arm Label: B. Strength training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Strength training | Arm Label: C. Low-Impact; Type: OTHER; Interventions: Behavioral: Low-Impact Exercise Control | Intervention Type: BEHAVIORAL; Name: Tai Chi; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): B. Strength training | Intervention Type: BEHAVIORAL; Name: Low-Impact Exercise Control; Assigned to Arm(s): C. Low-Impact
C: Arm Label: virtual reality balance training; Type: EXPERIMENTAL; Interventions: Behavioral: balance training | Arm Label: conventional balance training; Type: EXPERIMENTAL; Interventions: Behavioral: balance training | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: balance training; Assigned to Arm(s): conventional balance training, virtual reality balance training
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: ParkNet | Arm Label: II; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: ParkNet; Assigned to Arm(s): I | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): II

Answer: B